AIMSPRO is a potent anti-inflammatory, natural, biological therapy developed by Daval International Limited that has the proven capacity to switch off damaging pro-inflammatory processes at the molecular level, thus allowing the injured site to repair itself and prevent additional tissue damage.
Daval has completed clinical trials in Multiple Sclerosis and Systemic Sclerosis which have produced encouraging results. In addition, the company has sponsored a number of pre-clinical and clinical studies in indications such as Motorneurone Disease, Wound Healing and Alzheimer's Disease to determine possible functionality of Aimspro in these indications.
In human case studies of Alzheimer’s patients, AIMSPRO has stabilised the scores in some patients and in other cases, reversal trends were observed. These results are very encouraging, as other well-publicised studies have been reported to show limited efficacy by reducing a decline in scores but not by reversing the scores.
At Daval International, we believe that, in AIMSPRO, we may have the next efficacious Alzheimer's disease medication which has a decade-long proven safety record in human patients.
AIMSPRO is a potent anti-inflammatory, natural, biological therapy developed by Daval International Limited that has the proven capacity to reduce inflammation.
Daval International have carried out series of Case Studies to determine safety and efficacy of AIMSPRO® in multiple indications.